Low-dose aspirin may prevent colorectal cancer in Lynch syndrome patients

This announcement follows the CaPP3 study, which suggests that a daily low dose of 100 mg aspirin could reduce colorectal cancer risk in people with Lynch syndrome, a hereditary condition. The study indicates this lower dose may offer similar protective effects as higher doses but with fewer side effects, particularly bleeding. These findings build on previous research from the CAPP2 study and are published in The Lancet Gastroenterology & Hepatology.

Originally published by gnews